湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 关于受让药品上市许可的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 2025 年 3 月 25 日，湖南方盛制药股份有限公司（以下简称 "方盛制药"或"公司"）受让康溢医药有限公司（以下简称"康 溢医药"）持有的"喉咽清胶囊""浙贝止咳露（黄盒）"等合 计 20 个在香港特别行政区卫生署（以下简称"香港卫生署"） 注册的药品品种的所有权；并于同日与港捷有限公司（以下简称 "港捷公司"）、自然人赵国灏先生及向红梅女士签订《投资合 作协议》，拟在香港特别行政区成立合资子公司（以下简称"香 港合资公司"），注册资本 2,000 万港元，公司以自有资金出资 700 万港元，持股 35%，为公司控股子公司；该合资子公司成立 后，其将按照《投资合作协议》《药品品种转让协议》的相关约 定，与康溢医药就上述 20 个药品品种转让重新签订《药品品种 转让协议》并履行相关义务（详见公司 20 ...

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. plans to increase capital in its subsidiary Fangsheng R&D Co. with a total investment of 24 million yuan from the company and its partners, aiming to enhance its drug research and development capabilities in the Guangdong-Hong Kong-Macao Greater Bay Area [2][3][12] Summary by Sections 1. Transaction Overview - Fangsheng Pharmaceutical intends to invest 24 million yuan in Fangsheng R&D Co., with New Yuan Investment contributing 46 million yuan, and both Tongmu Technology and the core talent holding entity contributing 5 million yuan each. Post-investment, the shareholding structure will be Fangsheng Pharmaceutical 35%, New Yuan Investment 55%, Tongmu Technology 5%, and the core talent holding entity 5% [2][3] - The investment is classified as a related party transaction due to the involvement of New Yuan Investment, which is an affiliated entity. Related directors abstained from voting [2][3] - The investment does not constitute a major asset restructuring as per regulations, and it has been approved by the independent directors and the board of directors without needing shareholder approval [2][4] 2. Purpose and Reason for the Capital Increase - The capital increase aims to support the company's strategic development in the Guangdong-Hong Kong-Macao Greater Bay Area, leveraging local resources and policies to accelerate the R&D of traditional Chinese medicine projects and mitigate R&D risks [3][12] 3. Related Party Information - New Yuan Investment is controlled by the same individual as Fangsheng Pharmaceutical, establishing a related party relationship. The core talent holding entity will consist of key personnel from the company, which may include current directors and senior management [6][7] 4. Capital Increase Details - The registered capital of Fangsheng R&D Co. will increase from 20 million yuan to 100 million yuan, with the new capital structure reflecting the contributions from all parties involved [9][10] - The governance structure will include a board of directors with three members, where Fangsheng Pharmaceutical appoints two directors and the chairman [10][12] 5. Impact on the Company - Following the capital increase, Fangsheng R&D Co. will remain under the control of Fangsheng Pharmaceutical, allowing it to consolidate its financial statements. This move is expected to enhance the sustainability of R&D investments and facilitate the commercialization of innovative traditional Chinese medicine [12]

Core Points - The company held the second temporary meeting of the sixth board of independent directors on May 29, 2025, via remote voting, which was legally valid and complied with relevant regulations [2][3] - The meeting approved a proposal for capital increase and related transactions for its subsidiary, GuangDong Fangsheng R&D Pharmaceutical Co., Ltd. (Fangsheng R&D), aimed at enhancing its funding for drug research and development projects [2][3] - The capital increase is expected to improve the sustainability of R&D investments and mitigate the company's risks associated with new product development, ensuring no harm to minority shareholders [2][3] Summary by Sections - **Meeting Details** - The meeting was convened by independent director Yuan Xiong and attended by all three independent directors, confirming the quorum [2] - The proposal was submitted for review at the fourth temporary meeting of the sixth board [3] - **Proposal Approval** - The proposal received unanimous support with 3 votes in favor, 0 against, and 0 abstentions [3] - Independent directors involved in the voting were Gao Xueming, Du Shouying, and Yuan Xiong [3]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-059 湖南方盛制药股份有限公司 关于向控股子公司增资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容：方盛制药拟以现金 2,400 万元向控股子公司方盛融科进行增资， 新元产投、通牧科技、公司核心人才持股主体拟分别以现金 4,600 万元、500 万元、500 万元向方盛融科进行增资。本次增资完成后，方盛制药、新元产投、通牧科技及公司核 心人才持股主体将分别持有方盛融科 35%、55%、5%及 5%的股权。因公司能通过董事 会多数席位主导方盛融科经营决策，故对方盛融科具有控制权，方盛融科继续纳入公司 合并报表范围； 新元产投为公司关联法人，公司现任董事及高级管理人员可能参与核心人才持 股主体（尚未设立），因此本次增资事项构成关联交易，关联董事按规定回避了表决； 本次增资不构成《上市公司重大资产重组管理办法》规定的 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 该议案表决情况：3 票同意，0 票反对，0 票弃权，表决通过。 独立董事：高学敏、杜守颖、袁雄 2025年5月29日 第 1页，共 1页 （2025 年第二次临时会议） 湖南方盛制药股份有限公司（以下简称"公司"）第六届董事会 独立董事专门会议 2025 年第二次临时会议于 2025 年 5 月 29 日以通讯 表决的方式召开。会议通知及会议材料已于 2025 年 5 月 27 日以电子 邮件、微信、电话等方式通知全体独立董事。本次会议由独立董事袁 雄先生召集并主持，会议应出席独立董事 3 人，实际出席独立董事 3 人。本次会议参与表决人数及召集、召开程序符合《公司法》和《公 司章程》的有关规定，会议合法有效。会议审议并通过了《关于对控 股子公司增资暨关联交易的议案》： 本次对广东方盛融科药业有限公司（以下简称"方盛融科"）增 资将有效充实方盛融科药品研发项目的资金实力，将进一步增强方盛 融科研发投入的可持续性，能够在一定程度上分担公司的新品研发投 入及研发风险，不存在损害中小股东利益的情形，符合有关法律 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-058 湖南方盛制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 通过分配方案的股东会届次和日期 重要内容提示： ? 每股分配比例 A 股每股现金红利0.20元 ? 相关日期 股份类别 股权登记日 最后交易日 除权（息）日 现金红利发放 日 Ａ股 2025/6/6 － 2025/6/9 2025/6/9 ? 差异化分红送转： 否 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东 大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登 记结算有限责任公司上海分公司（以下简称"中国结算上海分公 司" ）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本439,081,360股为基 数，每股派发现金红利0.20元（含税），共计派发现金红利87,816,272 元。 第 1 页 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-058 湖南方盛制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.20元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/6 | － | 2025/6/9 | 2025/6/9 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东 大会审议通过。 二、 分配方案 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登 记结算有限责任公司上海分公司（以下简称"中国结算上海分公 司"）登记在册的本公司 ...

Group 1 - The stock price of Fangsheng Pharmaceutical (603998) closed at 10.53 yuan on May 30, 2025, up 6.26% from 9.91 yuan the previous week, with a market capitalization of 4.624 billion yuan [1] - The stock reached a high of 10.6 yuan and a low of 9.61 yuan during the week [1] - Fangsheng Pharmaceutical ranks 41st out of 68 in the traditional Chinese medicine sector and 3085th out of 5146 in the A-share market [1] Group 2 - The company is considering a new incentive plan, which will be based on future strategies and market conditions [2][4] - Market value management has been incorporated into the performance evaluation of some senior management, emphasizing communication with investors and a stable dividend policy [2][4] - The innovative traditional Chinese medicine product, Yao Xue Qu Feng Zhi Tong Granules, has submitted a listing application to the National Medical Products Administration and is currently under review [3][4]

Core Viewpoint - The company, Fangsheng Pharmaceutical, is experiencing growth in revenue and profit, particularly in its innovative drug segment, with a focus on maintaining a stable dividend policy and enhancing market presence in traditional Chinese medicine [1][2][4]. Weekly Highlights - As of May 23, 2025, Fangsheng Pharmaceutical's stock closed at 9.91 yuan, up 1.54% from the previous week, with a total market capitalization of 4.351 billion yuan [1]. - The company reported a projected revenue of 1.777 billion yuan for 2024, representing a 9.15% increase, and a net profit of 255 million yuan, reflecting a 36.61% growth [1]. Institutional Research Insights - The innovative drug segment showed significant sales growth, with the pediatric cough syrup increasing sales by 73% to nearly 90 million yuan, and the Xuanqi Jianbone tablets achieving 1.1 billion yuan in sales, a 280% increase [1]. - The company has implemented a multi-category collaborative development model to balance risks and support continuous growth [1]. Dividend Policy - The company has a history of cash dividends, with a total of 16 distributions amounting to approximately 623 million yuan. For 2024, it plans to distribute a total of 136 million yuan in dividends, which is 53.34% of the net profit attributable to shareholders [2][6]. Sales Performance - In the first four months of 2025, core product sales continued to show steady growth, although the overall market for respiratory drugs faced a decline due to various external factors [3]. - The company is focusing on cost control and efficiency improvements to enhance profitability despite revenue challenges [3]. Future Expectations - For 2025, the company aims to achieve revenue and net profit growth above the industry average by enhancing brand presence and expanding market share in innovative Chinese medicine [4]. - The strategic plan includes increasing investment in innovative drug development and optimizing resource allocation for research and marketing [4][5]. Company Announcements - Fangsheng Pharmaceutical has successfully recovered 83 million yuan in loans from Baijun Medical, with remaining unpaid principal of approximately 71.91 million yuan [7].

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-057 湖南方盛制药股份有限公司 关于转让控股子公司部分股权暨引进战略投资者的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 风险提示： 截至 2025 年 5 月 21 日，湖南省佰骏高科医疗投资管理有限公司（以下简称"佰骏 医疗"）已将《经修订和重述的和解和框架协议》中约定应于 2025 年 3 月 21 日向湖南 方盛制药股份有限公司（以下简称"公司"）偿还的借款全部偿还完毕，后续佰骏医疗 将继续按《经修订和重述的和解和框架协议》约定的还款计划向公司还款，公司将密切 关注相关事项的进展；请投资者注意相关风险，谨慎投资。 一、佰骏医疗归还公司欠款进展 佰骏医疗自 2024 年 10 月根据《经修订和重述的和解和框架 协议》的约定向公司还款，2024 年 10 月向公司偿还借款 1,600 万元，11 月、12 月分别向公司偿还借款 1,700 ...